Clinical Trial Update: Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study evaluating Fluciclovine F18 or Ga68-PSMA PET/CT imaging to enhance outcomes in prostate cancer. The study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Fluciclovine F18 (fluciclovine F-18)
• Ga68-PSMA PET/CT (gallium-68 PSMA PET/CT)

Snippet

Sponsor: Emory University | Conditions: Prostate Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING